IL310376B2 - Methods and compositions for treating angiogenic disorders using anti-VEGF factors - Google Patents

Methods and compositions for treating angiogenic disorders using anti-VEGF factors

Info

Publication number
IL310376B2
IL310376B2 IL310376A IL31037624A IL310376B2 IL 310376 B2 IL310376 B2 IL 310376B2 IL 310376 A IL310376 A IL 310376A IL 31037624 A IL31037624 A IL 31037624A IL 310376 B2 IL310376 B2 IL 310376B2
Authority
IL
Israel
Prior art keywords
vegf
agent
igg
vegf agent
amino acid
Prior art date
Application number
IL310376A
Other languages
English (en)
Hebrew (he)
Other versions
IL310376B1 (en
IL310376A (en
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67395742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL310376(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of IL310376A publication Critical patent/IL310376A/en
Publication of IL310376B1 publication Critical patent/IL310376B1/en
Publication of IL310376B2 publication Critical patent/IL310376B2/en

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41H—ARMOUR; ARMOURED TURRETS; ARMOURED OR ARMED VEHICLES; MEANS OF ATTACK OR DEFENCE, e.g. CAMOUFLAGE, IN GENERAL
    • F41H5/00—Armour; Armour plates
    • F41H5/02—Plate construction
    • F41H5/04—Plate construction composed of more than one layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL310376A 2018-01-26 2019-01-25 Methods and compositions for treating angiogenic disorders using anti-VEGF factors IL310376B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622382P 2018-01-26 2018-01-26
PCT/US2019/015160 WO2019147944A1 (en) 2018-01-26 2019-01-25 Methods and compositions for treatment of angiogenic disordres using anti-vegf agents

Publications (3)

Publication Number Publication Date
IL310376A IL310376A (en) 2024-03-01
IL310376B1 IL310376B1 (en) 2025-10-01
IL310376B2 true IL310376B2 (en) 2026-02-01

Family

ID=67395742

Family Applications (2)

Application Number Title Priority Date Filing Date
IL310376A IL310376B2 (en) 2018-01-26 2019-01-25 Methods and compositions for treating angiogenic disorders using anti-VEGF factors
IL276158A IL276158B2 (en) 2018-01-26 2019-01-25 Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL276158A IL276158B2 (en) 2018-01-26 2019-01-25 Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors

Country Status (16)

Country Link
US (3) US11524053B2 (https=)
EP (2) EP4495136A3 (https=)
JP (2) JP7517988B2 (https=)
KR (2) KR102861739B1 (https=)
CN (2) CN116059318A (https=)
AU (2) AU2019212622B2 (https=)
BR (1) BR112020015074A2 (https=)
CO (1) CO2020010384A2 (https=)
DK (1) DK3743091T3 (https=)
EA (1) EA202091786A1 (https=)
ES (1) ES3009668T3 (https=)
FI (1) FI3743091T3 (https=)
IL (2) IL310376B2 (https=)
MX (1) MX2021001424A (https=)
SG (1) SG11202007130RA (https=)
WO (1) WO2019147944A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途
JP2025508267A (ja) * 2022-03-04 2025-03-21 パノロス バイオサイエンス インコーポレイテッド ＶＥＧＦ－Ｇｒａｂ及びＰＤ－１又はＰＤ－Ｌ１拮抗剤を含む併用投与用組成物
CN117535299B (zh) * 2023-10-27 2024-12-06 北京生物制品研究所有限责任公司 分离的核酸分子、重组病毒或其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1793179A (zh) * 2005-11-04 2006-06-28 余波 包含vegf受体片段的优化融合蛋白质及其医疗应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
AU684498B2 (en) 1993-03-25 1997-12-18 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3011144B2 (ja) 1997-07-31 2000-02-21 日本電気株式会社 光スキャナとその駆動方法
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
JP2003529567A (ja) 2000-03-10 2003-10-07 インサイト・ビジョン・インコーポレイテッド 後眼部眼疾患を治療および予防する方法と組成物
EP1631317A2 (en) 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US7582726B2 (en) 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
EP1753442A2 (en) 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
EP1917024A2 (en) 2005-08-12 2008-05-07 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a vegf antagonist
AU2006279541A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
HRP20150884T1 (hr) 2006-03-21 2015-09-25 Genentech, Inc. Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
MX2009006202A (es) 2006-12-11 2009-06-22 Genentech Inc Composiciones y metodos para el tratamiento de neoplasma.
CN101205252A (zh) 2006-12-14 2008-06-25 上海中信国健药业有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
CN101575379B (zh) 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
WO2010067339A2 (en) * 2008-12-11 2010-06-17 Korea Advanced Institute Of Science And Technology Fusion protein capable of binding vegf-a and tnf-alpha
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
KR20260004598A (ko) 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
CN102924604A (zh) * 2012-11-01 2013-02-13 中国人民解放军军事医学科学院生物工程研究所 重组血管内皮生长因子受体及其编码基因与应用
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
RU2692652C2 (ru) 2013-03-13 2019-06-25 Джензим Корпорейшн Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
WO2015000181A1 (zh) 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
JP2016531149A (ja) 2013-09-11 2016-10-06 ニューロテック ユーエスエー， インコーポレイテッド カプセル化細胞療法カートリッジ
CN105026433B (zh) 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
JP6071099B1 (ja) 2014-01-25 2017-02-01 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管の新生又は成長を抑制する融合タンパク質及びその用途
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
AU2015318207B2 (en) 2014-09-16 2021-11-04 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US10894083B2 (en) 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
CA2981745C (en) 2015-04-07 2021-11-02 Zimmer, Inc. Convertible glenoid
ES2797901T3 (es) 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3412288A1 (en) 2017-06-08 2018-12-12 Galderma Research & Development Vegf inhibitors for use for preventing and/or treating acne
CN111032092A (zh) 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
MA50174A (fr) 2017-09-18 2020-07-29 Amgen Inc Formules de protéines de fusion vegfr-fc
CN109575140B (zh) 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
JP7536640B2 (ja) 2017-11-17 2024-08-20 アムジエン・インコーポレーテツド ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1793179A (zh) * 2005-11-04 2006-06-28 余波 包含vegf受体片段的优化融合蛋白质及其医疗应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.-E. LEE ET AL:, NOVEL GLYCOSYLATED VEGF DECOY RECEPTOR FUSION PROTEIN, VEGF-GRAB, EFFICIENTLY SUPPRESSES TUMOR ANGIOGENESIS AND PROGRESSION, 22 December 2014 (2014-12-22) *

Also Published As

Publication number Publication date
ES3009668T3 (en) 2025-03-31
CA3089481A1 (en) 2019-08-01
CN111741761A (zh) 2020-10-02
EP4495136A3 (en) 2025-04-23
CN111741761B (zh) 2023-04-18
SG11202007130RA (en) 2020-08-28
IL310376B1 (en) 2025-10-01
WO2019147944A1 (en) 2019-08-01
BR112020015074A2 (pt) 2020-12-08
KR20200112893A (ko) 2020-10-05
NZ766484A (en) 2025-08-29
EP3743091A4 (en) 2021-12-15
US20260097098A1 (en) 2026-04-09
US20240366721A1 (en) 2024-11-07
AU2019212622A1 (en) 2020-08-13
IL276158A (en) 2020-09-30
IL276158B1 (en) 2024-03-01
JP2021511061A (ja) 2021-05-06
AU2024204947A1 (en) 2024-08-08
IL310376A (en) 2024-03-01
KR20250052466A (ko) 2025-04-18
KR102861739B1 (ko) 2025-09-22
EP4495136A2 (en) 2025-01-22
WO2019147944A8 (en) 2020-08-20
IL276158B2 (en) 2024-07-01
EP3743091B1 (en) 2024-11-06
CO2020010384A2 (es) 2020-12-10
FI3743091T3 (fi) 2025-01-03
JP7517988B2 (ja) 2024-07-17
DK3743091T3 (da) 2025-01-06
CN116059318A (zh) 2023-05-05
US11524053B2 (en) 2022-12-13
JP2024149493A (ja) 2024-10-18
AU2019212622B2 (en) 2024-05-23
US12514905B2 (en) 2026-01-06
US20200353041A1 (en) 2020-11-12
EA202091786A1 (ru) 2020-10-20
MX2021001424A (es) 2021-06-23
EP3743091A1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
US12514905B2 (en) Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US20230136080A1 (en) Long-acting vegf inhibitors for intraocular neovascularization
ES2896493T3 (es) Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
CN105026433B (zh) VEGF与PDGFRβ双特异性融合蛋白及其用途
CN102906114A (zh) 双特异性二价抗vegf/抗ang-2抗体
CA2970384A1 (en) Fusion protein comprising a ligand binding domain of vegf and pdgf
KR20190031246A (ko) VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
CA3089481C (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
HK40123236A (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
HK40043110A (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
HK40043110B (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
HK40091843A (zh) 用於使用抗vegf剂治疗血管生成病症的方法和组合物
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
EA045081B1 (ru) Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2020022438A1 (ja) 網膜線維化を伴う眼疾患の処置剤
HK40126782A (zh) C5/vegf双特异性结合分子
CN120476152A (zh) C5/vegf双特异性结合分子